Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Holley (HLLY) Q1 2026 Earnings Call - Portfolio Rebalancing and Margin Expansion Offset Weather Headwinds
Holley reported a mixed Q1 2026, with net sales declining 3.7% to $147.3 million due to elevated distributor inventories and severe winter weather that delayed retail activity. Despite the top-line pr...
- Net sales declined 3.7% year-over-year to $147.3 million, driven by elevated distributor inventories and severe winter weather that delayed retail sell-through in January and February.
- Adjusted EBITDA remained flat at $27.3 million year-over-year, but adjusted EBITDA margin expanded 71 basis points to 18.5%, reflecting disciplined cost control and operational efficiency.
- Net income more than doubled to $7.3 million from $2.8 million in Q1 2025, as margin expansion and lower SG&A costs (down $1.4 million) offset revenue headwinds.
- +12 more takeaways
Solstice Advanced Materials Q1 2026 Earnings Call - Nuclear and Semiconductor Demand Drive Strong Results
Solstice Advanced Materials reported a robust first quarter in 2026, delivering $991 million in net sales, up 10% year-over-year, and $249 million in adjusted EBITDA. The results were driven by strong...
- Net sales reached $991 million, up 10% year-over-year, exceeding the top end of guidance.
- Adjusted EBITDA was $249 million, flat year-over-year but above guidance, with a 25.1% margin.
- Electronic materials sales surged 21% year-over-year, driven by robust semiconductor demand.
- +7 more takeaways
Astec Industries Q1 2026 Earnings Call - Backlog Surges Amid Tariff Headwinds
Astec Industries reported a 20.3% year-over-year increase in first-quarter net sales to $1.47 billion, driven by strong demand in the Materials Solutions segment and contributions from recent acquisit...
- First-quarter net sales surged 20.3% year-over-year to approximately $1.47 billion, reflecting strong organic growth and the impact of recent acquisitions.
- Adjusted EBITDA for the quarter declined to $30.3 million, down from the prior year, due to timing effects, higher freight costs, and tariff-related inflation.
- Full-year 2026 adjusted EBITDA guidance remains unchanged at $170 million to $190 million, with management expressing confidence in achieving targets.
- +7 more takeaways
Twin Disc Incorporated Fiscal Third Quarter 2026 Earnings Call - Defense Backlog and Margin Expansion Drive Strong Q3 Results
Twin Disc delivered a robust fiscal third quarter 2026, with sales jumping 19% year-over-year to $96.7 million and EBITDA surging 135% to $9.4 million. The growth was fueled by strong demand in Marine...
- Sales increased 19% year-over-year to $96.7 million, with organic growth of 7% excluding acquisitions and foreign exchange.
- EBITDA surged 135% year-over-year to $9.4 million, with EBITDA margins expanding by approximately 480 basis points.
- Gross margin improved to 28.1%, driven by higher volumes and successful margin improvement initiatives.
- +11 more takeaways
Taboola Q1 2026 Earnings Call - Raised Full-Year Guidance on Realize Momentum and Share Buybacks
Taboola delivered a strong start to 2026, with Q1 results beating the high end of guidance across all metrics, driven by continued adoption of its AI-powered Realize platform. Revenue grew 9% year-ove...
- Q1 2026 revenue grew 9% year-over-year to $466.4 million, beating the high end of guidance.
- Ex-TAC gross profit increased 11% year-over-year to $168.1 million, reflecting strong advertiser spend and Realize adoption.
- Management raised full-year guidance, now expecting revenue of $2.00 billion to $2.06 billion and ex-TAC gross profit of $760 million to $781 million.
- +10 more takeaways
EyePoint Pharmaceuticals Q1 2026 Earnings Call - DURAVYU Phase III Momentum Accelerates as Cash Runway Extends to Late 2027
EyePoint Pharmaceuticals reported a sharp revenue drop to $0.7 million in Q1 2026 as deferred licensing fees from the YUTIQ deal concluded, while operating expenses rose to $88 million to fund two Pha...
- Revenue fell to $0.7 million in Q1 2026 from $24.5 million in Q1 2025, driven by the conclusion of deferred revenue recognition from the 2023 YUTIQ licensing agreement.
- Operating expenses increased to $88 million from $73 million in the prior year period, primarily due to ongoing Phase III trials for DURAVYU and scaling of the Northbridge commercial manufacturing facility.
- The company reported a net loss of $85 million, or $0.99 per share, compared to a net loss of $45 million, or $0.65 per share, in the prior year period.
- +9 more takeaways
Triple Flag Precious Metals Q1 2026 Earnings Call - Record Start Driven by High-Margin Cash Flow and Accretive U.S. Copper Royalty
Triple Flag Precious Metals delivered a historic first quarter, shattering records across every key metric with 30,000+ GEOs, $129 million in adjusted EBITDA, and a 67% surge in operating cash flow pe...
- Q1 2026 marks the strongest quarter in company history across every key metric, including over 30,000 GEOs, $129 million in adjusted EBITDA, and $0.55 in operating cash flow per share.
- Operating cash flow per share surged 67% year-over-year, driven by high-margin exposure to rising gold and silver prices and the model functioning as intended.
- The company unlocked the high-grade E44 gold deposit at Northparkes, securing guaranteed minimum deliveries over seven years starting in 2030, aligning with Evolution Mining's block cave and mill expansion plans.
- +8 more takeaways
CVS Health Q1 2026 Earnings Call - EPS Guidance Raised to $7.30-$7.50 as Aetna Margins Recover
CVS Health delivered a strong first quarter, driving a 14% year-over-year increase in adjusted earnings per share to $2.57. The company responded to this momentum by raising its full-year 2026 adjuste...
- Adjusted EPS of $2.57 beat expectations, driving a full-year 2026 guidance raise to $7.30-$7.50, up from $7.00-$7.20.
- Revenue surged over 6% year-over-year to $100 billion, with adjusted operating income increasing 12% to $5.2 billion.
- Aetna’s medical benefit ratio improved to 84.6% in Q1, reflecting strong medical cost management and favorable prior year development.
- +12 more takeaways
LivaNova PLC Q1 2026 Earnings Call - OSA FDA Approval and Epilepsy Reimbursement Tailwind Drive Upgraded Guidance
LivaNova delivered a strong first quarter, posting 11% constant currency revenue growth driven by durable performance in its cardiopulmonary and epilepsy segments. The company raised its full-year 202...
- LivaNova reported Q1 2026 revenue of $362 million, an 11% increase on a constant currency basis, driven by strength across all regions and both core businesses.
- Full-year 2026 revenue growth guidance was raised to 7%-8%, up from 6%-7%, aligning with the high end of the company’s 2025-2028 growth framework.
- Cardiopulmonary revenue grew 14% in Q1, with heart-lung machine revenue in the high teens and consumables in the mid-teens, supported by Essenz placements and market share gains.
- +7 more takeaways
NACCO Industries Q1 2026 Earnings Call - Strong Profit Growth Driven by Utility Coal and New Infrastructure Contracts
NACCO Industries delivered a robust start to 2026, with first-quarter operating profit jumping 43% year-over-year and adjusted EBITDA rising 28%. The gains were anchored by improved efficiency at Miss...
- First-quarter operating profit surged 43% year-over-year and 45% sequentially, with adjusted EBITDA up 28% year-over-year to $16.4 million.
- Mississippi Lignite Mining Company drove utility coal segment strength, with operating profit doubling year-over-year to $7.4 million as cost per ton fell and reclamation activities offset reduced deliveries during a power plant outage.
- Contract mining revenues jumped 32% year-over-year, fueled by the commencement of a multi-year dragline services contract for the U.S. Army Corps of Engineers in Florida and increased limestone deliveries.
- +7 more takeaways